Is COO Stock Attractive as MyDay Gains Meet Asia-Pacific Pressure

• MyDay premium contact lenses delivered double-digit fiscal Q2 growth, with toric and multifocal revenues up 7% organically, though CooperVision's full-year organic growth outlook was trimmed to 3.5-4.5%
• Asia-Pacific sales fell 6% organically to $130.6 million in Q2 due to weakness in Japan, China, and Korea, with management expecting another decline in Q3
• COO recorded a $271.6 million net pre-tax charge for fertility media recall litigation and carries $2.46 billion in total debt against $138.8 million in cash, though fiscal 2026 free cash flow is projected at roughly $650 million

Summary: The Cooper Companies (COO) Stock Analysis

Company Overview:

The Cooper Companies (COO) operates two primary healthcare platforms: CooperVision (contact lenses) and CooperSurgical (fertility and surgical products). The stock currently holds a Zacks Rank #3 (Hold) rating with neutral recommendations.

Key Performance Highlights:

• MyDay brand: Delivered double-digit growth in fiscal Q2 2026, driven by daily silicone hydrogel adoption
• Toric and multifocal revenues: Rose 7% organically
• CooperSurgical: Generated $358 million in Q2 revenues, up 6% organically
• Fertility revenues: Increased 10% organically to $143.8 million
• Free cash flow outlook: Raised to approximately $650 million for fiscal 2026 (excluding litigation payouts)

Major Challenges:

• Asia-Pacific weakness: Region sales declined 6% organically to $130.6 million in Q2, with continued declines expected in Q3 due to softness in Japan, China, and Korea
• CooperVision growth outlook: Trimmed to 3.5-4.5% for full-year organic growth
• Litigation costs: $271.6 million net pre-tax charge related to CooperSurgical's December 2023 fertility media recall, including $324.1 million in settlement liabilities offset by $52.5 million in insurance recoveries

Financial Position:

• Cash: $138.8 million as of April 2026
• Total debt: $2.46 billion
• Momentum Score: D (indicating limited near-term price momentum)

Market Implications:

While COO demonstrates strength in premium contact lenses and myopia control products, investors face uncertainty from Asia-Pacific headwinds, litigation-related costs, and high leverage. The stock presents a balanced risk-reward profile suitable for patient investors awaiting clearer operational improvements.